Skip to content
DataLookout
Menu

NCT07631013

Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Dec 31, 2026 to Oct 30, 2026
    • Site details revised
  2. Notable Eligibility criteria expanded, about 39 words
    • Interventions: TROP2 CAR/IL-15 TGFBR2 KO NK cells (Drug) to TROP2 CAR/IL-15 TGFBR2 KO NK cells (Drug)
    • Study description expanded, about 4 words
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year

Arms and interventions

ESC/EXP: Phase 1 Part 1-ESC and Part 2-EXP Treatment with TROP2 CAR/IL-15 TGFBR2 KO NK CellsExperimental

Participants will receive 2 TGFBR2 TROP2 CAR/IL15 CAR injections on Day 0 and Day 21 at the assigned dose level

Drugs: TROP2 CAR/IL-15 TGFBR2 KO NK cells

Sites

1 site in 1 country

  • MD Anderson Cancer CenterHouston, Texas, United States